Extravasation of chemotherapy

Area of Science:

• Oncology
• Pharmacology
• Patient Safety

Background:

• Chemotherapy extravasation is a serious risk during cancer treatment.
• Leakage of cytostatic agents into surrounding tissues can lead to severe patient harm.
• Anthracycline extravasation is particularly destructive.

Purpose of the Study:

• To review the current understanding and management of chemotherapy extravasation.
• To highlight the importance of international guidelines in clinical practice.
• To discuss preventative strategies for severe extravasation injuries.

Main Methods:

• Review of existing international guidelines on chemotherapy extravasation.
• Analysis of the role of dexrazoxane as an antidote for anthracycline extravasation.
• Synthesis of current clinical practices for managing chemotherapy leakage.

Main Results:

• International guidelines provide valuable tools for managing extravasation.
• Dexrazoxane is an effective antidote for preventing tissue destruction from anthracycline extravasation.
• Increased focus has improved the clinical approach to chemotherapy extravasation.

Conclusions:

• Chemotherapy extravasation poses significant risks but is increasingly manageable.
• Adherence to guidelines and use of specific antidotes like dexrazoxane improve patient outcomes.
• Ongoing attention to extravasation management is crucial for patient safety in oncology.